As Chief Operating Officer at ENB Therapeutics, Sandy Harm plays a pivotal role in steering the company’s strategic direction and operational excellence in the development of small molecule inhibitors targeting selective solid tumors. With a robust background in pharmaceutical and healthcare leadership, Sandy’s expertise spans...
As Chief Operating Officer at ENB Therapeutics, Sandy Harm plays a pivotal role in steering the company’s strategic direction and operational excellence in the development of small molecule inhibitors targeting selective solid tumors. With a robust background in pharmaceutical and healthcare leadership, Sandy’s expertise spans the entire spectrum of Research and Development Operations, from clinical trials to commercialization. Her extensive experience in clinical research, particularly in Oncology and Infectious Diseases, positions her as a key player in advancing ENB’s innovative therapeutic solutions.
Under Sandy's operational oversight, the company has achieved significant milestones, including the successful approval of an Investigational New Drug (IND) application and the management of three annual IND submissions. These accomplishments underscore her proficiency in navigating the complexities of regulatory compliance and project management within the pharmaceutical landscape. Sandy’s strategic vision is complemented by her ability to foster cross-functional team leadership, ensuring that clinical, regulatory, and manufacturing efforts are seamlessly integrated to drive ENB’s mission forward.
Moreover, Sandy’s involvement in Investigator Initiated Studies and medical affairs strategy highlights her commitment to enhancing scientific collaboration and advancing patient care. Her skills in market access and sales effectiveness further bolster ENB’s position in a competitive market, allowing the company to effectively communicate the value of its innovative therapies to healthcare providers and stakeholders. As a member of the executive leadership team, Sandy Harm continues to leverage her comprehensive knowledge and experience to propel ENB Therapeutics toward its goal of delivering groundbreaking treatments for patients with unmet medical needs.
